Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01472029 |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach(HerFLOT) |
| completed |
| Phase 2 |
| 53 |
| AIO-Studien-gGmbHOTHER |
| 1 |
| Jun 19, 2017 |
| clinicaltrials |
| NCT02913066 | S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 88 | Mianyang Central HospitalOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00582660 | Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib(UAB0040) | completed | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 41 | University of WashingtonOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01231399 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | completed | Phase 1 / Phase 2 | 6 | City of Hope Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01798147 | Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | unknown | Phase 2 | 24 | Johannes Gutenberg University MainzOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | terminated | Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT03114085 | Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 170 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | May 15, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases(BOS3) | withdrawn | Phase 2 / Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)(MEGAN) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00816634 | Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma(XP versus XT) | unknown | Phase 2 | 94 | Samsung Medical CenterOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT01357486 | Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis(PRODIGE 21) | completed | Phase 2 | 160 | University Hospital, BordeauxOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | terminated | Phase 2 | 5 | Seoul National University HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT03130712 | A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | unknown | Phase 1 / Phase 2 | 10 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02725996 | By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy | unknown | Phase 2 | 140 | Southwest Hospital, ChinaOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03124498 | A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA | unknown | Phase 1 / Phase 2 | 55 | Chuan An Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | terminated | Phase 2 | 3 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00828984 | Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer(PRIMIER) | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | terminated | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01007552 | A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts | completed | Phase 2 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | terminated | Phase 1 / Phase 2 | 6 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT03084380 | Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00322361 | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | completed | Phase 2 | 566 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 16, 2017 | clinicaltrials |
| NCT01206049 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations(GOC-B-P) | completed | Phase 2 | 88 | Vejle HospitalOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT01522937 | A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer | completed | Phase 2 | 94 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01507064 | Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma(LANEX) | completed | Phase 2 | 40 | Cardarelli HospitalOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT03069508 | Clemizole HCl for Subjects With Hepatocellular Carcinoma | unknown | Phase 2 | 12 | Eiger Group International, Inc.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02956772 | Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 190 | Hunan Provincial People's HospitalOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01755013 | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | terminated | Phase 2 | 19 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01273662 | Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 45 | National Taiwan University HospitalOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03048123 | HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B | completed | Phase 2 | 79 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03046979 | Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)(HCC) | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00273312 | Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 7, 2017 | clinicaltrials |
| NCT00361231 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2017source: clinicaltrials